PBYI · Puma Biotechnology, Inc.
$9.24
+0.13 (+1.43%)
At close · Aug 21
Market Cap
$476.97M
Shares
51.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.24
Open$9.20
Day$9.07–9.48
52W close$4.34–9.49
Avg vol 30d323K
Short int4.1M · 8.0% float · 13.9d
Short vol74%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+13%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+44%
trailing
YTD return
+55%
this year
Relative strength
+32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.99% of float · ▲ +5.6% MoM · 13.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
EPS growth
−2%
Y/Y
Free cash flow
$41.7M
Valuation
P/E 17.8
in line
Balance sheet
$7.1M
net cash
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Third Quarter 2026
Total Revenue
Initiated
$56M – $59M
prior qtr $56.5M
midpoint +1.8% QoQ
Royalty Revenue
Initiated
$2M – $3M
Net Income
Initiated
$2M – $3.5M
Gross to Net Adjustment
Maintained
26% – 27%
Jun 30, 2026
26% – 27%
changed to
Aug 6, 2026
26% – 27%
New Full Year 2026
Total Revenue
Initiated
$224M – $231M
prior FY $228.37M
midpoint −0.4% Y/Y
Royalty Revenue
Initiated
$19M – $22M
Gross to Net Adjustment
Maintained
26.5% – 27.5%
Jun 30, 2026
26.5% – 27.5%
changed to
Aug 6, 2026
26.5% – 27.5%
Net Income
Initiated
$17M – $20M
Prior guidance
period ended
· from the 8-K filed May 7, 2026
Net Product Revenue
· Second Quarter 2026
$50M – $52M
Royalty Revenue
· Second Quarter 2026
$2M – $3M
License Revenue
· Second Quarter 2026
$0
Total Revenue
· Second Quarter 2026
$52M – $55M
Gross to Net Adjustment
· Second Quarter 2026
27% – 28%
Guided vs delivered
· last 2 settled
Total Revenue
Third Quarter 2025
guided $48M – $51M
$54.48M
Beat +10.1%
Total Revenue
Full Year 2025
guided $212M – $222M
$228.37M
Beat +5.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.99% of float · ▲ +5.6% MoM · 13.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $9 · 95%
Range high $9
vs 200-day avg +35%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $93.9M | June 30, 2026 | — |
| Net cash provided by operating activities | $17M | first six months of 2026 | — |
| Non-GAAP adjusted net income non-GAAP | $8.3M | first six months of 2026 | — |
| Royalty revenue | $5.8M | first six months of 2026 | — |
|
|
|||
| Non-GAAP adjusted net loss non-GAAP | $1.9M | first quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PBYI
this stock
Puma Biotechnology, Inc.
|
$476.97M | +55.3% | -0.9% | 17.8 | 8.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PBYI | +4.6% | +15.8% | +43.9% | +16.5% | +55.3% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +6.0% | +12.2% | +32.4% | +14.0% | +43.0% |
Key facts
CIK
1401667
CUSIP
74587V107
13F (30d)
136 filings
136 filers
Visit website
Investor relations